A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjogren's Syndrome

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjogren's Syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Seletalisib (Primary)
  • Indications Sjogren's syndrome
  • Focus Proof of concept; Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 17 Oct 2017 This trial has been Discontinued in Greece.
    • 09 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Jul 2018.
    • 09 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top